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Objective. The objective was to compare the postprandial glycemic and insulinemic responses to nutrition bars containing either
cross-linked RS type 4 (RS4XL) or standard wheat starch in normoglycemic adults (n = 13; age = 27±5 years; BMI = 25±3 kg/m2).
Methods. Volunteers completed three trials during which they consumed a glucose beverage (GLU), a puﬀed wheat control bar
(PWB), and a bar containing cross-linked RS4 (RS4XL) matched for available carbohydrate content. Serial blood samples were
collected over two hours and glucose and insulin concentrations were determined and the incremental area under the curve (iAUC)
was calculated. Results. The RS4XL peak glucose and insulin concentrations were lower than the GLU and PWB (P < .05). The
iAUC for glucose and insulin were lower following ingestion of RS4 compared with the GLU and PWB trials. Conclusions. These
data illustrate, for the first time, that directly substituting standard starch with RS4XL, while matched for available carbohydrates,
attenuated postprandial glucose and insulin levels in humans. It remains to be determined whether this response was due to the
dietary fiber and/or resistant starch aspects of the RS4XL bar.
1. Introduction
Consumption of whole grains has been recommended to
improve insulin sensitivity and lower serum glucose and
insulin concentrations. Whole grain consumption of three
servings or more per day was among changes that were
included in the 2005 dietary guidelines to reduce the risk
of acquiring chronic diseases [1]. Whole grains are major
sources of dietary fiber (DF), yet typical DF consumption
patterns do not meet the recommended 25–35 g per day.
Therefore, eating more grain-based fiber-rich foods is war-
ranted to help optimize health and potentially manage some
chronic metabolic conditions.
At present, resistant starches (RSs) have drawn broad
interest for their health benefits and functional properties
[2, 3]. Initial clinical studies demonstrated that RS has prop-
erties similar to soluble fiber, shows promising physiological
benefits in humans, and may prevent disease. Several poten-
tial physiological benefits ascribed to RS include attenuation
of blood glucose and insulin levels in both healthy and
diabetic individuals, positive eﬀects on large bowel health
and prevention of colonic cancer, increased absorption of
minerals, serving as a prebiotic, and increased fat oxidation
[3–9]. There are four basic “types” of RS. Type 1 (RS1)
is composed of starch granules embedded in indigestible
plant material. Type 2 (RS2) is native granular starch with
a B-type x-ray pattern, such as found in potato and high-
amylose maize. Type 3 (RS3) is crystallized starch and
maltodextrins made by alternate cooking/cooling processes
on starchy materials. Type 4 (RS4) is chemically modified
starch typically through esterification, crosslinking (RS4XL),
or transglycosylation.
The majority of human clinical trials have been con-
ducted using only RS2 or RS3, which tend to illustrate
decreased blood glucose following consumption of foods
with these starches added [3, 6, 10–15]. It is diﬃcult to
fully understand the beneficial capacity of RS due to the
methods used in the human clinical trials that tested the
eﬃcacy of RS. For example, one clinical trial failed to control
both the amount and source of all the ingredients [16].
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In a study investigating the eﬀects of esterified RS type 4
(RS4OSA), Heacock et al. [17] reported that RS4OSA decreased
peak glucose and insulin levels when it was administered
in water, but RS is typically consumed in foods. Also, in
studies by Behall et al. [18, 19], the amount of available
carbohydrate diﬀered, which limits the capacity to determine
if the attenuation of glucose and insulin was due to the RS or
the fact there was less available carbohydrate. Furthermore,
Robertson et al. [6] provided packets containing RS2 for
volunteers to sprinkle on their food thereby not illustrating
the eﬀects that might be achieved when provided in the
food supply. Taken together, the available data illustrate
that RS has the potential to lower blood glucose. However,
few clinical trials testing the eﬀects of RS have controlled
ingredients and the amount of available carbohydrates to
better delineate the role of RS in aﬀecting the insulin
and glucose responses, and no published clinical trials
investigating the glucose lowering potential of RS4XL exist.
Therefore, the aim of this study was to investigate
the acute eﬀects of consuming RS4XL incorporated into a
nutrition bar, while controlling for nonstarch ingredients
and available carbohydrates, on postprandial glucose and
insulin responses in young adults with a randomized clinical
trial (NCT00687960, clinicaltrials.gov).
2. Materials and Methods
2.1. Subjects. The Institutional Review Board of Kansas State
University approved the study, and written informed consent
was obtained from all volunteers prior of the study. Inclusion
criteria were no diagnosis of acute or chronic metabolic
diseases, free of gastrointestinal disorders, body mass index
of 23–30 kg/m2, and nonsmokers. Volunteers were screened
for glucose tolerance using a two hour 75 g glucose tolerance
test prior to participation. Eighteen healthy younger adults
were recruited and 13 participated in and completed the
study, while the other five did not meet the criteria. Of
the 13 volunteers (age = 27±5 years, BMI = 25±3 kg/m2,
HOMA = 0.94±0.34), 7 were females and 6 were males.
Based on BMI values, these volunteers all have similar risks
for all-cause and obesity-related mortality [20]. Also, an oral
glucose tolerance test was performed prior to enrollment to
ensure each volunteer had normal glucose tolerance.
2.2. Oral Glucose Tolerance Test. Prior to enrollment, volun-
teers arrived after a 12 hours overnight fast. Blood samples
were drawn by finger stick at baseline and 120 minutes
after ingesting 75 g of glucose in solution (296 mL; Sun-
Dex 75 g, Fisher Scientific, Houston, Tex, USA). Samples
were analyzed in duplicate for glucose concentration (YSI
2300 STAT, Yellow Springs, Ohio, USA). The oral glucose
tolerance test was used to confirm the absence of prediabetes
or diabetes.
2.3. Study Design. All trials were performed at the Human
Metabolism Laboratory at Kansas State University. Volun-
teers completed three trials via a controlled randomized
crossover design. During each trial, volunteers consumed
Table 1: Ingredients and their concentrations by relative weight (%
total) in the test bars.
PWB RS4XL
Puﬀed Wheata 34 —
Resistant Starch type 4b — 34
Corn Syrupc 20 20
Wheat Germd 18 18
Brown Sugare 11 11
Waterf 10 10
Gum Acaciag 6 6
Panodan 150Kh 1 1
a Quaker Oats
b Fibersym RW; MGP Ingredients, Inc.
c Karo light corn syrup
d Kretschmer Original Toasted
e C&H Pure Cane Sugar, golden brown
f Tap water (Manhattan, Kan)
g TIC Gums
h Danisco
one of the following: dextrose solution (198 mL of a standard
75 g oral glucose tolerance beverage; GLU), a control bar
containing puﬀed wheat (65 g; PWB), and a bar containing
cross-linked RS4XL bar (80 g; RS4XL) (Table 1). All treat-
ments were designed to provide 50 g of available carbohy-
drate (Table 2). All trials were completed by each volunteer
with at least a seven-day washout between testing days. This
was a quasiblinded experiment in that one treatment was a
beverage and the other two were in bar form, which were
randomly administered using a Latin Square design. Some
female volunteers did not use oral contraceptives, but others
used either contraceptive pills or progesterone injections.
Regardless, the females were scheduled to perform all the
trials during the follicular phase of their menstrual cycle and
each served as their own control.
2.4. Experimental Bars. The only altered ingredients between
bars were either puﬀed wheat or RS4XL (Table 1). Briefly,
the nutrition bars were prepared by adding puﬀed wheat
or cross-linked RS4 to wheat germ. The dose of the RS4XL
(27.2 g) was intended to be close to the dose used previously
[6], whereby a significant improvement in insulin sensitivity
was observed. The remaining ingredients (water, corn syrup,
brown sugar, gum acacia, and Panodan 150 K) were heated
to 85◦C over 4 minutes, poured over the dry ingredients,
and then manually mixed quickly until dry ingredients were
evenly distributed throughout the mixture. The mixture was
scooped into a metal pan, pressed evenly throughout the
pan, and allowed to cool for 20 minutes before cutting into
bars. Crude nutrient analysis was determined by proximate
analysis, while total dietary fiber was assessed independently
(Medallion Labs, Minneapolis, Minn) (Table 2). Available
carbohydrate was calculated as the diﬀerence between total
carbohydrate and dietary fiber as used previously [9].
Controlling for available carbohydrate in this fashion has
been shown to aﬀect the glycemic response, while controlling
for RS content does not necessarily aﬀect the glycemic
response [21].
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Table 2: Nutrient composition of each treatment per dose (GLU =
198 mL; PWB = 65 g; RS4 = 80 g).
GLUa PWBb RS4bXL Δ
e
Total Energy (kcal) 200 261 326 (65 kcal, 125%)
Carbohydrate (g)
Total 50 56 71 (15 g, 127%)
Availablec 50 51 51 (0 g, 0%)
Total Dietary Fiber (g)d — 5 20 (15 g, 400%)
Fat (g) — 1 2 (1 g, 200%)
Protein (g) — 7 6 (1 g, 86%)
a glucose tolerance test beverage (Sun-Dex, Fisher Scientific, Houston, Tex)
b Crude nutrient composition was determined by proximate analysis (total
energy, total fat, total protein, total carbohydrate).
c derived by subtracting total dietary fiber from total carbohydrate.
d dietary fiber analysis was performed by Medallion Laboratory (Minneapo-
lis, Minn).
e diﬀerence (subtraction value, % value) between bars.
2.5. Food Tolerance Test. The postprandial test (two-hours
with seven blood samples) was modified from Flammang
et al. [22]. During each test, volunteers arrived to the
laboratory after a 10–12 hour overnight fast. An indwelling
catheter (Terumo, 22gx1, Terumo Medical Corporation,
Elekton, Md) was inserted into a forearm vein. The line
was kept patent with 0.9% isotonic saline solution (0.9%
sodium chloride USP, B. Braun Medical Inc., Irvine, Calif).
Ten minutes after inserting the IV catheter, the fasting blood
sample was collected. Thereafter, the volunteers consumed
the assigned food item for that day. The solution (GLU) or
bar was consumed within 10 minutes. The treatment bars
were served with 198 mL of water (to match the fluid that
was consumed during the GLU trial). Relative to taking the
first bite of food, blood samples were collected at−10, 10, 20,
30, 60, 90, and 120 minutes.
2.6. Blood Samples. After collection, blood samples were
centrifuged at 2,500 rpm for 15 minutes at 4◦C. The plasma
was extracted from the vacutainer and immediately analyzed
in duplicate for glucose (YSI 2300, Yellow Springs Instru-
ments, Yellow Springs, Ohio) with the remainder stored
at −80◦C. The frozen samples were analyzed in duplicate
for insulin using an endocrine assay (LINCOplex kit, St.
Charles, Mo), and measured by Luminex100 (Austin, Tex)
instrumentation. Once the samples were analyzed, the
highest value attained over the 120 minutes was determined
to be the peak value, with the diﬀerence between baseline and
peak determined to measure the change from fasting to peak.
Glucose and insulin areas under the curve (iAUC) were
determined using the trapezoid method (GraphPad Prism
v 5.02, La Jolla, Calif). This approach was adapted from a
previous RS feeding study [18]. Fasting insulin and glucose
values were also used to calculate the homeostasis model
assessment (HOMA) [23].
2.7. Diet and Physical Activity Records. A diet record was
completed by the volunteers prior the first test of the study.
Volunteers were instructed on how to record their intakes.
They were requested to then eat the same foods from that
diet recorded the day before the second and third trials. This
procedure was used previously [24]. Also, volunteers were
requested to record their physical activity for the day before
testing and perform that same activity (or inactivity) the day
prior to the subsequent tests.
3. Data Analysis
Sample size estimation was calculated using PASS software
(NCSS 2007 and PASS 2005, Kaysville, Utah). Based on
results from previously published data using RS2 [6], six
volunteers were determined necessary (power > 0.80, and
P < .05) to detect significant diﬀerences in glucose and
insulin responses. A repeated measures analysis of variance
(SPSS version 11.5, Chicago, Ill) was used to determine
significant main eﬀects with significance set at P = .05.
Paired t-tests (SPSS version 11.5, Chicago, Ill) were used to
determine diﬀerences between and among trials for peak,
change from baseline to peak and iAUC values for glucose
and insulin. The comparisons of interest were primarily
between the two bars, with the glucose treatment providing
a standard point of reference.
4. Results
The three meals provided practically the same amount (50-
51 g) of available carbohydrate (Table 2). Both nutrition bars
contained similar amounts of protein and were low in fat,
but the RS4XL bar contained four times the dietary fiber
(20 g versus 5 g) compared to the PWB. Approximately one-
fifth of the total dietary fiber in the RS4XL bar was from
gum arabic (∼4.4 g) with the remainder (∼15.6 g) being from
RS4XL. The meals diﬀered in their calculated food-energy
contents (200–326 kcal, Table 2) because their compositions
diﬀered and because their weights to deliver 50 g of available
carbohydrates diﬀered.
The commercially available RS4XL used in this study
contains 0.4% phosphors, 10.6% moisture, 91.9% total
dietary fiber by AOAC-International Method 991.43, and
83.3% RS by a modified Englyst method [25]. At the time
of preparing the 80 g bar of RS4XL, the amount of RS added
was ∼20 g (dry solids) according to the formula in Table 1
and the composition of Fibersym RW, while the amount
of gum arabic added was 4.4 g (dry solids). At the time of
analyzing the finished 80 g bar, the bar contained 20 g of total
dietary fiber (Table 2). Assuming no loss of gum arabic in
the preparation of the RS4XL bar, the 4.4 g loss of dietary
fiber could be attributed to some damage to the RS, which
increased its digestibility. Assuming the ratio of RS to dietary
fiber remains constant at 0.9 in partially damaged RS4XL,
then the 80 g bar of RS4XL fed to the subjects contained∼14 g
RS, implying∼70% was maintained following preparation of
the bar.
The RS4 bar elicited decreased glucose and insulin
concentrations at several time points (Figure 1) during the
120 minutes postprandial period as compared with GLU and
PWB. Also, consumption of the RS4 bar led to an attenuation
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Figure 1: Depiction the glucose (a) and insulin (b) responses over two hours following the consumption of each (Glu, PWB, and RS4)
treatment. Values represent each mean ± SE. A: significant diﬀerence with PWB; B: significant diﬀerence with RS4.
of peak glucose and insulin, and significant diﬀerences from
baseline to peak and iAUC values glucose and insulin when
compared with GLU and PWB (Table 3). The PWB bar
attenuated the peak glucose and insulin responses and the
iAUC for glucose and insulin compared with GLU. The
percent increase from baseline to peak was not diﬀerent (P =
.068) from GLU for glucose, while it was for insulin.
5. Discussion
These data, for the first time, indicate that eating RS4XL
from wheat in place of standard wheat starch significantly
decreased postprandial insulin and glucose responses. These
results are in line with others investigating the insulin and/or
glucose lowering eﬀects when RS (typically RS2) is added
to foods or incorporated in the diet [6, 16, 18, 26, 27],
while a few reported no eﬀect of RS2 or RS3 on glycemia
[7, 9]. Results from several other clinical trials reported
RS decreased the glycemic response, but those studies had
volunteers sprinkle RS onto the food instead of it being
an ingredient in the food, mixed only with water, ate large
(up to 388 g) portion sizes, failed to control for available
carbohydrate, and/or the food eaten contained diﬀerent
ingredients with varying amounts of available carbohydrate
[6, 16, 18, 26, 27].
One of the more surprising outcomes was that RS4XL sig-
nificantly attenuated the glycemic and insulinemic responses
even when high glycemic ingredients were eaten. This
observation is critical for consumers and food scientists
when looking for or creating foods to control blood glucose
levels in that they may not need to avoid foods containing
corn syrup or sugar for the purpose of regulating their
blood glucose levels. That is, these data clearly indicate that
even though two foods contain identical concentrations of
glycemic ingredients, the presence of RS4XL may significantly
lower glucose and insulin responses. In the case of the bars
that were tested, the volunteers actually consumed more corn
syrup and brown sugar in the RS4XL bar since they consumed
15 g more of that bar than the PWB bar. Yet, the glycemic and
insulinemic responses for the RS4XL bar were significantly
attenuated compared with the PWB bar that was matched
for available carbohydrate yet contained less (by weight)
sugar and corn syrup (Table 3). This does not imply that
eating sugar and corn syrup is healthy, but that foods high
in RS4XL attenuate glycemia and insulinemia compared with
those with standard whole wheat starch when sugar and corn
syrup are present and account for ∼30% of the energy. This
is of interest as sugar and corn syrup have been the target
of criticism for potentially contributing to the obesity and
diabetes epidemics [28–30].
The observed attenuation of the glucose and insulin
responses might be a result of high concentrations of DF
and/or RS in the RS4XL bar. In separate in vitro analyses for
DF and RS, this version of cross-linked RS4 has been shown
to contain 91.9% dietary fiber and 83% resistant starch [25].
Relative to clinical trials that used RS2, Le Leu et al. [31]
recently reported that several varieties of RS2 only contain
18–60% dietary fiber and 46–53% RS. Thus, this cross-linked
form of RS4 likely elicited the significant diﬀerence due to a
relatively high content of fiber and RS.
This study is not without limitations. While we did
observe a significant attenuation in glucose and insulin
responses when RS4XL was incorporated into the bar, it is
not possible to know whether the same eﬀects would occur
in individuals with insulin resistance or other metabolic
conditions. It could be suggested that the current dose used
for the RS4XL bar (80 g) might be greater than one would
choose to consume at one sitting. A more realistic approach
might be to base the doses on average serving sizes, but that
would only oﬀer 15–20 g of available carbohydrate in the
RS4XL bar. That said a previous study [26] had volunteers
consume treatment foods that were nearly five-fold greater.
Likewise, we were trying to match the amount of available
carbohydrate at 50 g, which is recommended for glycemic
index testing [32]. Another potential confounding issue,
especially when comparing the bars with the solution, is the
diﬀerence in gastric emptying [33]. Also, the total energy
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Table 3: Values for the incremental areas under the curves of glucose and insulin concentrations during each trial00. Mean ± SE; diﬀerent
letters within a row indicates significant diﬀerence (P < .05).
GLUC PWB RS4XL
Glucose
iAUC (mmol/L • 2 hr) 140± 31A 84± 17B 28± 11C
Peak (mmol/L) 7.30± 0.5A 6.33± 0.3B 5.40± 0.2C
Increase (%) 60.5± 10A 42.7± 6A 20.4± 3B
iAUC (pM • 2 hr) 17, 575± 2, 236A 8, 758± 1, 132B 3, 659± 974C
Peak (pM) 344± 36.7A 211.5± 20.1B 162.3± 22.6C
Increase (%) 335± 53.2A 243.0± 49.3B 126.3± 45.8C
contained within the RS4XL bar did not take into account
the energy provided via fermentation of the RSXL into short
chain fatty acids. Lastly, we cannot determine the mechanism
for the eﬀect observed. It is reasonable to conclude that
the RS4XL caused the eﬀects, as it was the only ingredient
diﬀerence, but it is not possible to determine how much of
the change was attributable to the dietary fiber or the RS that
is contained within RS4XL.
In conclusion, this is the first published randomized
clinical trial to investigate the glucose and insulin lowering
potential of RS4XL. Additionally, this is one of a few clinical
studies where the treatments were matched for available
carbohydrate and the RS was substituted directly for standard
starch in the tested food, while all other ingredients were
identical. This ingredient and nutrient control minimizes
confounding factors that are present when treatments are
matched instead for total carbohydrate [18] or when dif-
ferent ingredients are used in clinical trials [16]. While it is
unknown what component (dietary fiber or resistant starch)
of RS4XL lowered glucose and insulin, it is clear that RS4XL
was responsible for the observed diﬀerences between bars.
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